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Research
Epidemiologic studies have consistently found
significant associations between exposure to
drinking water disinfection by-products
(DBPs) and human cancers (Cantor et al.
1998; Freedman et al. 1997; Hildesheim et al
1998; King and Marrett 1996; McGeehin
et al. 1993; Villanueva et al. 2006b; Zierler
et al. 1988); however, the reported odds ratios
were typically < 2.0 and quite variable. Studies
of adverse reproductive outcomes associated
with DBP exposures have yielded inconsistent
results (e.g., King et al. 2000; Savitz et al.
1995, 2006; Waller et al. 1998). As suggested
by Villanueva et al. (2006a), additional infor-
mation, including individual physiologic and
genetic characteristics, recent relevant expo-
sures, and direct environmental measure-
ments, may improve exposure assessment and
thus the precision of disease risk estimates
associated with human exposure to disinfec-
tion by-products.
We previously conducted a study to assess
whether, in addition to drinking water, house-
hold water uses that generate aerosols or
release volatile chemicals are an important and
measurable source of trihalomethane (THM)
exposure (Backer et al. 2000). Increases in
blood THM levels among the 10 subjects who
showered or bathed were highly variable and
fell into two significantly different groups,
suggesting possible differences in THM
metabolism. For example, the mean (± SD)
increase in blood bromoform levels was 8.2 ±
2.97 pg/mL for one group of ﬁve participants
and 21.2 ± 4.26 pg/mL for the remaining ﬁve
participants. Miles et al. (2002) reported ﬁnd-
ing similar clustering of blood THM levels
after various household water use activities.
The variation of blood THM levels may
have been the result of differences in physio-
logic characteristics or recent related expo-
sures. For example, THM blood levels depend
not only on tap water quality, but also on the
nature and frequency of water use activities
(Nuckols et al. 2005).
Blood levels of THMs after environmen-
tal exposures may reflect individual differ-
ences in drug metabolizing enzyme gene
polymorphisms. For example, brominated
THMs are substrates for glutathione S-trans-
ferase theta (GSTT)–mediated glutathione
conjugation reactions (Landi et al. 1999).
Individuals with the active enzyme may clear
brominated THMs from the blood more
rapidly than similarly exposed individuals
with the null genotype, and thus have lower
levels (Landi et al. 1999).
Polymorphisms in metabolic genes may
also mediate disease risks. GSTT1 polymor-
phisms may be important in determining an
individual’s risk for non-Hodgkin lymphoma,
stomach cancer, and liver cancer associated
with exposure to dichloromethane (Kerridge
et al. 2002; Lan et al. 2001; Setiawan et al.
2000). The cytochrome P450 gene CYP2D6
(cytochrome P450 2D6) is involved in
metabolism of xenobiotic chemicals (Nebert
and Russell 2002). It has 5–10 variants affect-
ing metabolic activity to influence levels of
parent compound and metabolites that may
be responsible for adverse health effects. For
CYP2E1 (cytochrome P450 2E1), Infante-
Rivard (2004) found that exposure to high
levels of THMs affected fetal growth only in
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BACKGROUND: We previously conducted a study to assess whether household exposures to tap
water increased an individual’s internal dose of trihalomethanes (THMs). Increases in blood THM
levels among subjects who showered or bathed were variable, with increased levels tending to
cluster in two groups.
OBJECTIVES: Our goal was to assess the importance of personal characteristics, previous exposures,
genetic polymorphisms, and environmental exposures in determining THM concentrations in
blood after showering. 
METHODS: One hundred study participants completed a health symptom questionnaire, a 48-hr
food and water consumption diary, and took a 10-min shower in a controlled setting. We examined
THM levels in blood samples collected at baseline and 10 and 30 min after the shower. We
assessed the signiﬁcance of personal characteristics, previous exposures to THMs, and speciﬁc gene
polymorphisms in predicting postshower blood THM concentrations.
RESULTS: We did not observe the clustering of blood THM concentrations observed in our earlier
study. We found that environmental THM concentrations were important predictors of blood
THM concentrations immediately after showering. For example, the chloroform concentration in
the shower stall air was the most important predictor of blood chloroform levels 10 min after the
shower (p < 0.001). Personal characteristics, previous exposures to THMs, and speciﬁc polymor-
phisms in CYP2D6 and GSTT1 genes were signiﬁcant predictors of both baseline and postshower-
ing blood THM concentrations as well as of changes in THM concentrations associated with
showering.
CONCLUSION: The inclusion of information about individual physiologic characteristics and envi-
ronmental measurements would be valuable in future studies to assess human health effects from
exposures to THMs in tap water.
KEY WORDS: CYP2D6, CYP2E1, disinfection by-products, drinking water disinfection, GSTT1,
showering exposures, trihalomethanes. Environ Health Perspect 116:57–63 (2008).
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phism. In addition, specific variants of
CYP2E1 could be involved in the metabolic
activation of trihalomethane-related carcino-
gens (Gao and Zhang 1999). 
The primary objective of this study was to
determine the major contributors to variabil-
ity in blood THM levels after showering, and
particularly to evaluate whether the clustering
of blood THM levels after showering that we
observed in our previous study was a spurious
finding because of our small sample size or
was real based on physiologic and genetic
differences among individuals.
Materials and Methods
Institutional review board approvals. The
institutional review boards of the Centers
for Disease Control and Prevention (CDC),
the National Institutes of Health, the General
Clinical Research Center (GCRC) at the
University of Pittsburgh, and Battelle
Memorial Institute approved this study proto-
col. We have complied with all applicable
requirements for protection of human sub-
jects. Study participants gave written informed
consent before the study.
Study participants. This study was con-
ducted at the GCRC clinical research labora-
tory during July–September 2004. We
recruited potential study participants from a
panel who volunteered to participate in
research at the GCRC. Study participants pro-
vided blood samples for a complete blood
count, standard blood chemistry panel, and
enzyme activity and genotyping, including
CYP2D6 (accession no. AY545216; GenBank;
http://www.ncbi.nlm.nih.gov/GenBank),
CYP2E1 (accession no. DQ515958; GenBank),
GSTT1 [glutathione S-transferase (theta class);
accession no. BC007065; GenBank], and
GSTM1 [glutathione S-transferase (µ class);
accession no. BC024005; GenBank]. Eligible
subjects (18–45 years of age) had a normal
blood screen, were not pregnant (veriﬁed for
women with a pregnancy test on the day of
the study), not nursing an infant, and physi-
cally able to take a shower and provide blood
samples. All subjects were nonsmokers, did
not drink an average of more than one alco-
holic beverage per day, were willing to abstain
from drinking alcoholic beverages for 2 days
before the study, did not take acetaminophen
ﬁve or more times a week, and were free from
chronic lung disease and asthma.
Estimates of the frequency of GSTT1
positive in the various populations range from
15 to 80% (El-Masri et al.1999; Garte et al.
2001; Raimondi et al. 2006). Therefore, we
used the initial GCRC genotyping results to
identify potential participants who were
GSTT1 positive. We recruited 43 study par-
ticipants with GSTT1 positive (GSTT1 wild
type or GSTT1 heterozygous null) and 57
with GSTT1 homozygous null genotypes. We
then assessed these individuals for their
CYP2D6 and CYP2E1 genotypes.
Of 112 volunteers, 100 met eligibility cri-
teria, agreed to participate, and completed
study activities over a 6-week period. A ran-
dom sample of nine subjects repeated the
study for analysis of the repeatability of our
results (analysis not shown here). There were
five family groups, and 11 subjects were
blood relatives of another study participant.
Questionnaire and diary. We collected
questionnaire data for each participant just
before conducting study activities. Speciﬁcally,
we collected data on demographics (age, sex,
race), height, weight, occupation, smoking,
use of chloral hydrate, recent respiratory
symptoms, and activities that were sources of
THM exposure (bathing, swimming, using
hot tub or sauna, washing clothes or dishes) or
that might affect the activity of the enzymes of
interest [alcohol consumption (Dupont et al.
2000), using solvents or cleaners containing
volatile organic compounds (VOCs)].
Study participants recorded in a diary
how much tap water they drank during the
48 hr preceding study activities. We estimated
cold water intake as number of 8-oz cups.
Weisel and Chen (1994) found that heating
water increased THM concentrations and
that household exposures calculated using the
THM concentration in heated water were
50% higher than those calculated using the
THM concentration in cold water. Thus, we
estimated hot water intake as 2 × [number of
bowls of soup made with water + 8-oz cups of
hot coffee + 8-oz cups of hot tea + (servings of
hot cereal × 0.66) + (servings of rice or pasta
× 0.66) + (servings of vegetables cooked in
water × 0.05)].
Certain foods induce synthesis of some of
the metabolic enzymes of interest in this
study. Subjects recorded in a diary how many
servings of broccoli, cauliflower, lettuce,
onions, garlic, watercress, and black tea they
ate/drank during the 48 hr preceding study
activities (Kall et al.1996; Leclercq et al.
1998; Le Marchand et al. 1999; Stupans et al.
2001). We estimated the intake of foods of
interest as the number of servings of broccoli,
cauliﬂower, and lettuce + (servings of onions
× 0.2) + (servings of garlic, watercress, and
black tea × 0.1).
Study activities. To minimize the influ-
ence of foods, beverages, alcohol consump-
tion, and selected medications on study
results, participants fasted overnight, did not
drink any alcoholic beverages or take medica-
tions that affect the enzymes of interest (i.e.,
dextromethorphan, chlorpheniramine, chloral
hydrate) during the 48 hr before study activi-
ties, and did not drink caffeinated beverages
on the day of the study. Urine samples were
collected immediately before and after study
activities for future analysis of haloacetic acid
concentrations and one extra blood sample
was collected for future genotyping.
On the day of the study, subjects com-
pleted the questionnaire and provided two
10-mL blood samples, took a 10-min temper-
ature-controlled shower, provided one 10-mL
blood sample first 10 min and then 30 min
after turning off the shower, and then
ingested a 250-mg chlorzoxazone tablet
(Lemmon Company, Sellersville, PA). One
10-mL blood sample was drawn 2 hr later for
analysis of chlorzoxazone metabolism as a
measure of CYP2E1 enzyme activity. Study
participants remained at the study site for an
additional 2 hr to ensure that no adverse reac-
tion to chlorzoxazone occurred.
To limit study participants’ exposure to
THMs unrelated to the shower, we required
that they not ﬂush the toilet or run tap water
while in the study area, dry off and dress as
quickly as possible, and stay in a separate
room away from further exposure to THMs.
We provided study participants with THM-
free bottled drinking water.
Biological specimens. Whole blood sam-
ples for THM analysis were collected by a cer-
tified phlebotomist using Vacutainer tubes
processed to remove VOC contamination
(Cardinali et al. 1995). Samples were ana-
lyzed for THM levels using headspace solid
phase microextraction (SPME) coupled with
gas chromatography (GC) and high-resolu-
tion mass spectrometry (MS). Analyte quan-
tiﬁcation was based on stable isotope dilution
(Bonin et al. 2005).
In vivo CYP2E1 activity. CYP2E1 is
inducible but the genotype does not predict
the phenotype. We therefore measured
CYP2E1 activity by the in vivo chlorzoxa-
zone test (Frye et al. 1998; Scott et al. 1999).
Serum concentrations of chlorzoxazone and
its major metabolite, 6-hydroxychlorzoxa-
zone, were measured by high performance
liquid chromatography. We used the ratio of
6-hydroxychlorzoxazone to chlorzoxazone as
a phenotypic measure of CYP2E1 activity.
GSTT1, CYP2D6, and CYP2E1 geno-
typing. Genomic DNA was extracted from
peripheral blood using the PureGene DNA
Isolation Kit (Gentra Systems, Inc.,
Minneapolis, MN) according to the manufac-
turer’s instructions. We screened the
CYP2D6*3 and 4 and CYP2E1*5 variant alle-
les with TaqMan allele discrimination-based
assays using the Applied Biosystems 7700 sys-
tem (Applied Biosystems, Foster City, CA).
For the differential polymerase chain reaction
(PCR) method for GSTT1 genotyping, we
used a housekeeping gene (β-globin) as an
internal control (Pemble et al. 1994).
Positive and negative PCR controls were
included with each ampliﬁcation reaction. For
both genotyping analyses, we used previously
Backer et al.
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controls for the homozygous wild-type, hetero-
zygous, and homozygous variant genotypes
with every PCR analysis to verify reproducibil-
ity of the assay and to confirm accuracy of
genotype classiﬁcations. Approximately 10%
of randomly selected samples were repeated
blindly for verification of genotyping assays.
All results were interpreted independently by
two laboratory staff members, and no discor-
dant genotype classiﬁcations were identiﬁed.
Environmental samples. Air. We collected
three air samples near the subject’s breathing
zone: a preexposure bathroom sample, a
10-min time-integrated sample in the
enclosed shower stall during the shower, and
a 5-min time-integrated postshower sample in
the unventilated bathroom. Air samples were
collected using evacuated stainless steel canis-
ters. Filled canisters were sealed and shipped
to Battelle (Columbus, OH) for analysis. We
analyzed the samples for THMs by auto-
mated GC/MS using a modified version of
U.S. Environmental Protection Agency
method TO-14 (Winberry et al. 1990). Full
details of air sampling and analysis procedures
are available elsewhere (Gordon et al. 2006).
Water samples. The shower head was
modified to allow remote water sampling.
Duplicate samples were collected 5 min after
each shower began. Participants were
instructed to set the shower water tempera-
ture between 104 and 105°F (40–41°C).
Shower water temperature was monitored by
the participant and study staff via a digital
thermometer in the shower stall and a remote
radio thermometer outside the bathroom.
Water samples were collected in borosilicate
glass vials containing sodium thiosulfate to
quench further THM formation and phos-
phate buffer to standardize pH between 6.0
and 6.5. We analyzed water samples for
THM levels using headspace SPME–GC/MS
with quantification based on stable isotope-
dilution (Cardinali et al. 2004).
Statistical analyses. We conducted statis-
tical analyses using SAS, version 9.0 (SAS
Institute Inc., Cary, NC). We evaluated asso-
ciations of predictor variables (e.g., demo-
graphics, genotype, THM concentrations in
air, THM concentrations in water) with
THM levels in blood 10 min after showering
and THM level changes (10 min minus base-
line) after showering. For changes in THM
levels in blood, the logs of the differences
(10 min minus baseline) were used as our
outcome measure. The residuals from the
final models were evaluated for normality;
this assumption was satisﬁed for each model.
We used generalized estimating equations
to model these data to account for the correla-
tions caused by having multiple members of
the same family in the analyses. Univariate
analyses were run separately for each THM.
We chose independent variables that had a
p-value ≤ 0.10 for inclusion in initial multi-
variate models and used a backward selection
approach to select a ﬁnal model for each out-
come measure. After choosing a final model
for the change in blood levels of THMs at
10 min after exposure, we wished to investigate
the contribution of individual variables to the
total variability explained by all variables. The
partial r2 measures the marginal contribution
of one explanatory variable when all others are
already included in the model. Partial r2 values
were not available in the generalized estimat-
ing equations procedure, so our r2 results were
based on a least-squares analysis.
Results
In this article,  we present the results from the
analysis of environmental samples and blood
samples collected at baseline and at 10 min
after the shower.
Approximately half (54) of our 100 study
participants were women, and most (73) were
white. Eighty-ﬁve study participants reported
eating at least one of the foods of interest
within 24 hr of the study, and about one-ﬁfth
reported having upper respiratory symptoms
within 4 weeks of the study. Eleven subjects
reported exposure to bleach, and ﬁve or fewer
people reported exposures to speciﬁc solvents
or other VOCs within 24 hr of the study (data
not shown). Over half (57) of our study par-
ticipants were GSTT1 null; 43 were GSTT1
positive (GSTT1 wild type or GSTT1 hetero-
zygous null). Nearly three-fourths (74) of our
study participants were CYP2D6 wild type
(*1/*1), 21 were heterozygous (*1/*3 or *1/*4),
pand 5 were homozygous recessive (*4/*4).
The results of the chlorzoxazone assay for
CYP2E1 enzyme activity were as follows:
median, 0.54; interquartile range, 0.37–0.72;
range, 0.21–1.72. Consistent with previous
reports (Gurley et al 2002; Lucas et al 1998),
the distribution of 6-hydroxychlorzoxazone/
chlorzoxazone ratios was skewed toward lower
values (i.e., lower metabolic activity).
Results from the analyses of THMs in
shower water and shower stall air samples are
presented in Table 1. Chloroform was present
in the highest concentrations in both water
and air samples, followed by concentrations of
bromodichloromethane, dibromochloro-
methane, and bromoform. We prevented air
circulation during study activities; thus, THM
air concentrations in the 10-min integrated
shower samples and the 5-min integrated
postshower samples were similar.
The distribution of THMs in water sam-
ples by consecutive study participant number
over the 12-week study period is shown in
Figure 1. Bromoform levels were > 6 µg/L for
all but one of the first 12 participants and
< 2 µg/L for the remaining participants. The
drop in bromoform concentration during the
study was likely the result of unusually high
rainfall that occurred in Pittsburgh at the time
of the study. It is likely that the unusually high
water volume diluted the local water source,
thus diluting tap-water bromine concentra-
tions. Despite the very low levels of bromo-
form in the water, we were able to detect
bromoform in 75 of the baseline blood sam-
ples and in 98 of the 10-min postshowering
blood samples. The concentrations of mono-
and dibrominated compounds also decreased
over the study period. Over the study period,
chloroform levels in shower water varied from
< 40 µg/L to nearly 100 µg/L.
THM concentrations in blood samples
and the changes in concentration (10 min
postshower minus baseline) are presented in
Table 2. The blood THM data for one study
participant seemed anomalous (> 2 SDs from
the sample means at baseline and after show-
ering) and thus were removed from these
analyses. Blood THM levels are presented in
Figure 2. THM concentrations measured
10 min after the shower were log-normally
distributed.
The magnitude of postshower increases
in blood THMs reflected THM concentra-
tions in shower water and air. The data for
Trihalomethane exposure and enzyme polymorphisms
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Table 1. THM concentrations [median (interquartile range)]a in environmental samples: tap water
collected during showering and three integrated air samples (preexposure baseline, a time-integrated
sample in the shower stall while the participant is showering, and a time-integrated sample to cover the
5-min postshower exposure period).
Air (µg/mb)
Preexposure 10-min integrated 5-min integrated post-
THMc,d Water (µg/L) baseline sample shower stall sample shower bathroom sample
Bromoform 1.0 (0.4–1.5) < LODe 2.69 (1.46–4.13) 2.69 (1.46–4.34)
Dibromochloromethane 9.5 (6.2–13) < LOD 27.6 (20.5–38.8) 29.5 (20.4–38.6)
Bromodichloromethane 21 (18–24) < LOD 75.0 (59.1–86.2) 78.7 (64.1–87.8)
Chloroform 66 (56–72) 1.31 (0.69–1.61) 245 (212–279) 248 (221–288)
Total THMs 98 (91–102) 1.31 (0.69–1.61) 353 (314–394) 362 (328–408)
LOD, limit of detection.
aRange is the 25th and 75th percentiles. bLOD for THM concentrations in air: bromoform, 2.1 µg/m3; dibromochloromethane,
1.7 µg/m3; bromodichloromethane, 1.3 µg/m3; chloroform, 0.98 µg/m3. cLOD for trihalomethanes in water: bromoform:
0.12 µg/L; dibromochloromethane: 0.24 µg/L; bromodichloromethane: 0.48 µg/L; chloroform: 0.92 µg/L. dWhen the concentra-
tion of an analyte was below the LOD, the concentration was replaced with the LOD/√2. eExcept for chloroform, the THM
concentrations in air were below the LOD. Only chloroform was included in the total THM value for air.chloroform are presented in Figure 3. The
blood concentrations of bromoform reﬂected
water concentrations of bromoform.
Variables that were statistically signiﬁcant
(p ≤ 0.10) in univariate analyses were included
in initial models for THM levels in blood. We
included water and air (10-min integrated air
sample) THM levels; height; weight; body
mass index (BMI); sex; race; age; alcohol con-
sumption; and recent swimming, sauna use,
and water-related household activities (doing
laundry, washing dishes). We also included
genotype (for CYP2D6 and GSTT1), and the
ratio of 6-hydroxychlorzoxazone to chlorzoxa-
zone (for CYP2E1) in our models. A summary
of statistics from GENMOD procedure (SAS
Institute Inc.) modeling blood levels of THMs
10 min postshowering and the change in
THM concentrations (10 min postshower
minus baseline) is presented in Table 3.
Ten minutes after the shower, shower water
concentration was an important predictor of
individual blood levels of all the THMs except
chloroform. For bromodichloromethane and
chloroform, which are more volatile than the
other THMs, air concentrations were impor-
tant in determining blood levels. 
Previous exposures and personal charac-
teristics also affected blood THM levels at 10
min postshowering. Swimming was the most
important predictor of blood bromoform lev-
els, and higher BMI was associated with lower
blood levels of all THMs except chloroform.
CYP2D6 genotypes with decreased metaboliz-
ing activity were significant predictors of
increased blood bromodichloromethane and
chloroform levels, and the GSTT1 null (inac-
tive enzyme) genotype was associated with an
increase in chloroform blood levels.
The important predictor variables in the
models for the changes (10 min postshower
minus baseline) in blood THM concentra-
tions were similar to those that were impor-
tant in predicting 10-min postshower blood
THM concentrations (Table 3). For example,
the CYP2D6 enzyme variant with decreased
metabolizing activity was associated with
higher 10-min postshower blood concentra-
tions of bromodichloromethane and chloro-
form and with higher postshower changes in
blood concentrations of bromodichloro-
methane and dibromochloromethane. Similar
to the 10-min postshower concentrations, the
GSTT1 null genotype was associated with
greater changes in chloroform concentrations
10 min postshower. Environmental concen-
trations, hot water intake, and BMI were
important in determining the postshower
changes in blood levels of all THMs.
The importance of the environmental con-
centrations of THMs in determining the
increase in blood levels was confirmed when
we examined the partial r2. For chloroform
and bromoform, the partial r2 for variables in
Backer et al.
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Table 2. THM concentrations (ng/L) in blood samples collected from 99 study participants immediately
before showering and blood samples collected from the same participants 10 min after completing the
shower, and the changes in THM concentrations (10 min postshower minus baseline). 
Median concentration Median difference
(interquartile rangea) (interquartile range)
THMb Baseline postshower 10 min minus baseline 10 min postshower
Bromoform 0.91 (0.7–1.2) 4.0 (2.2–6.2) 2.9 (1.5–4.5)
Dibromochloromethane 1.2 (0.71–2.1) 32 (21–46) 31 (20–42)
Bromodichloromethane 2.2 (1.4–3.5) 69 (54–88) 64 (49–84)
Chloroform 10 (6.7–18) 200 (150–240) 187 (144–230)
aRange is the 25th–75th percentiles. bLimit of detection (LOD) for THMs in blood: bromoform: 0.55 ng/L; dibromo-
chloromethane: 0.23 ng/L; bromodichloromethane: 0.24 ng/L; chloroform: 2.4 ng/L. When the concentration of an analyte
was below the LOD, the concentration was replaced with LOD/√2.
Figure 1. THM concentrations in shower water. Data are presented by study ID number in numeric and
chronologic order over the 12-week study period (n = 99).
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the ﬁnal model included 0.3841 (p < 0.001)
for log(chloroform concentration in air) and
0.3434 (p < 0.0001) for log(bromodichloro-
methane concentration in air), respectively. r2
for the other variables in these models were
smaller by an order of magnitude. For bromo-
form and dibromochloromethane, the partial
r2 for variables in the final model included
0.86 (p < 0.0001) for log(bromoform concen-
tration in water) and 0.80 (p < 0.0001) for
log(dibromochloromethane concentration in
water), respectively. Again, r2 for other vari-
ables in the model were smaller by at least an
order of magnitude.
Discussion
In this study, we found that environmental
concentrations (water, air) were the most
important predictors for increases in blood
THM levels from a showering exposure. We
also found that personal characteristics, previ-
ous exposures, and metabolic enzyme poly-
morphisms were significant modulators of
shower-related increases in blood concentra-
tions for some THMs.
In assessing the effects of personal charac-
teristics on internal levels of an environmen-
tal contaminant, it is important not only to
carefully measure exposure, but also to limit
exposure variability. In the present study, we
limited experimental dose variability by con-
trolling the duration and temperature of the
shower. We also enhanced exposure measure-
ments by including concentrations of THMs
in shower air as well as water in our analyses.
We did not see the clustering of blood THM
concentrations that we observed in our previ-
ous study (Backer et al. 2000), suggesting
that the earlier results were likely a spurious
effect attributed to a small (n = 10) sample
size. However, consistent with the earlier
study, we found an association between
shower water and postshowering blood
THM concentrations. In the previous study,
the average chloroform concentration in
shower water was 31 µg/L and the average
change in blood concentration (10 min post-
shower minus baseline) was approximately 90
ng/L. Here, the geometric mean chloroform
concentration in shower water was approxi-
mately 64 µg/L, and the average change in
blood concentration (10 min postshower
minus baseline) was approximately 190 ng/L.
Our results demonstrate that blood chloro-
form and other THM levels are related to
tap-water levels in a dose–response manner
and that showering is an important source of
THM exposure that should not be over-
looked in conducting studies of disease risk.
Once exposure to exogenous chemicals
occurs, genetic variability in metabolic
enzymes may play a role in determining the
relative internal dose of parent compound
and metabolites. In our previous study
(Backer et al. 2000), we noted that THM
concentrations in blood samples collected
10 min after a shower appeared to cluster in
two groups. In this study, we did not replicate
this observation; however, we found that
enzyme gene polymorphisms were signiﬁcant
predictors for levels of the most highly chlori-
nated THMs in blood 10 min after the
shower. When compared with the wild type,
the reduced activity genotypes CYP2D6
(*4/*4) or GSTT1 null were associated with
increased chloroform (and thus presumably
decreased metabolites) in the blood 10 min
after exposure. Although not significant, the
heterozygous extensive metabolizing CYP2D6
(*1/*4) genotype suppressed the magnitude of
the increases in chloroform and bro-
modichloromethane in the blood 10 min
after exposure. The phenotypic variation in
CYP2E1 did not affect blood THM levels in
our study. Our results provide support for the
idea that individual genotypic variation can
modulate systemic exposure, and thus health
risks, associated with exposure to THMs by
affecting the relative concentrations of parent
THMs and detoxified or activated metabo-
lites present in an individual’s blood.
We were particularly interested in the
effects of genetic polymorphisms on bromo-
form metabolism. Our choice of study site
was based on historical data indicating we
could expect tap-water levels of all THMs to
be high enough to be detectable in blood after
a 10-min shower. However, as noted, tap-
water bromoform concentrations decreased to
concentrations < 2 µg/L after the ﬁrst 12 sub-
jects. Consequently, blood levels of bromo-
form 10 min postshowering were consistently
low (often below detection) and not highly
variable, and we were unable to address the
effects of genetic polymorphisms on bromo-
form levels in blood.
Although evaluating individual genotypes
is likely to be useful in interpreting the
results of epidemiologic studies of environ-
mental exposures, it requires collecting a bio-
logic specimen from each study participant,
thus increasing the resources needed for a
given study. To enrich our study populations
with the genotypes of interest without mak-
ing the sample size prohibitively large, we
prescreened study participants for specific
genotypes. Even with this enrichment, we
were able to consistently detect differential
effects associated with enzyme polymor-
phisms only for chloroform.
Overall, our study results indicate that the
most important predictors of blood THM con-
centrations after showering are the environmen-
tal exposures themselves. This is particularly
evident in the decrease in blood bromoform
levels that paralleled the decrease in water levels
over the study period. Using the geometric
mean concentration of bromoform as the
reference, the ratios of bromodichloromethane
Figure 3. Associations between the change in chloroform concentrations in whole blood (10 min postshower minus baseline) and THM concentrations in shower
water (A) and the 10-min integrated shower air sample (B). The correlation (r2) between changes in chloroform concentrations in whole blood and in shower
water was 0.60 (p < 0.001). The correlation between chloroform concentrations in water and the 10-min integrated shower air sample was 0.63 (p < 0.001) (n = 99). 
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A Band dibromochloromethane were similar in
the shower water (20.1 and 8.5, respectively)
and in the air during the shower (25.2 and
9.2, respectively). Chloroform is the most
volatile of the THMs, and the ratio of chloro-
form to bromoform was of the same magni-
tude but higher in shower air (99.7) than in
shower water (63.5). Again using the geometric
mean concentration of bromoform as a refer-
ence, the ratios of bromodichloromethane
and chloroform were very similar when com-
paring the levels in blood 10 min after the
shower. Thus, immediately after showering,
the relative amounts of the different THMs
were consistent with what was in shower
water and air. 
Environmental exposure levels in both
water and air were also signiﬁcant predictors
of the changes in blood THMs between base-
line and 10 min postshowering. This is con-
sistent with reports by Xu and Weisel (2005a,
2005b) that uptake of chloroform during
showering occurs through both dermal and
inhalation exposure routes, respectively.
Increased BMI was a predictor for smaller
changes in blood THM levels. Compared
with subjects with lower BMIs, subjects with
higher BMIs tended to have lower blood
THM levels at 10 min postshowering; this
association may be attributed to THMs parti-
tioning into lipid (Batterman et al. 2002).
These results suggest that, given a specific
exposure and a baseline measurement, per-
sonal characteristics such as BMI can modu-
late the distribution of these lipophilic DBPs
within the body.
Of interest is the association of swimming
with blood levels of bromoform and chloro-
form. Swimming within 48 hr of study activi-
ties was the most important predictor of
blood bromoform levels 10 min after expo-
sure. This may be because the bromoform
levels were very low in our study showers
compared with levels present in swimming
pool water and in poolside air (Fantuzze et al.
2001). Because bromoform is a carcinogen
(National Toxicology Program 1989), studies
assessing health risks from THM exposures
should query subjects about chlorinated pool
use for a more complete assessment of bromi-
nated THM exposure. From our data, it is
not clear why swimming would have a nega-
tive association with the postshower change in
blood chloroform concentration. This associ-
ation disappears with adjustment for baseline
values; however, the pros and cons of such
adjustment are not always clear (Glymour
et al. 2005).
In summary, our analyses indicate that
individual polymorphisms in GSTT1 and
CYP2D6 genes were significant but minor
predictors of blood trihalomethane levels 10
min after showering and of the differences
between blood levels 10 min after showering
and those at baseline. We demonstrated that
it is important to quantify environmental
contaminant levels when deﬁning dermal and
inhalation exposure to THMs. We also found
that personal characteristics, such as BMI,
and recent exposures, such as swimming and
drinking hot tap water–based beverages,
affected postshowering blood THM levels.
Our study suggests that information about
individual susceptibility factors, such as
enzyme gene polymorphisms, together with
information about individual physiologic
characteristics and environmental measure-
ments, should be included as a component of
exposure assessment in future studies of
human health risks from exposure to THMs.
Backer et al.
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Table 3. Summary of statistics from the multivariate generalized linear models procedure modeling the log
of blood levels of THMs at 10 min postshower and the log of the differences in blood THMs (10 min post-
shower minus baseline). 
Trihalomethane Parameter Estimate 95% CIs
10 min postshower
Bromoform Intercept 1.21# 0.77 to 1.64
BMIa –0.02** –0.04 to –0.01
Swamb 1.43# 1.29 to 1.56
Water concentrationc 0.56# 0.46 to 0.65
Dibromochloromethane Intercept 2.63# 2.28 to 2.99
BMI –0.02** –0.03 to –0.01
Water concentration 0.08# 0.06 to 0.11
Air concentrationd 0.01** 0.003 to 0.02
Bromodichloromethane Intercept 3.18# 2.84 to 3.52
BMI –0.01* –0.02 to –0.003
Saunae 0.14* 0.02 to 0.25
Hot water intake –0.002# –0.003 to –0.001
CYP2D6*1/*4f –0.11 –0.26 to 0.04
CYP2D6*4/*4 0.20* 0.005 to 0.39
Water concentration 0.03* 0.01 to 0.05
Air concentration 0.01* 0.001 to 0.01
Chloroform Intercept 4.58# 4.37 to 4.80
Chlorine cleanersg –0.15* –0.27 to –0.02
Hot water intake –0.002# –0.003 to –0.001
CYP2D6*1/*4 –0.08 –0.20 to 0.04
CYP2D6*4/*4 0.31** 0.08 to 0.54
GSTT1 nullh 0.10 0.00 to 0.20
Air concentration 0.003# 0.002 to 0.004
10 min postshower minus baseline
Bromoform Intercept 1.91# 1.47 to 2.36
BMI –0.03** –0.05 to –0.01
Hot water intake –0.003# –0.004 to –0.002
Log water concentrationi 1.01# 0.92 to 1.10
Dibromochloromethane Intercept 1.62# 1.23 to 1.98
BMI –0.01** –0.02 to 0.005
Hot water intake –0.003# –0.004 to –0.002
CYP2D6*1/*4 –0.11 –0.25 to 0.03
CYP2D6*4/*4 0.23* 0.06 to 0.40
Air concentration 0.01* 0.001 to 0.013
Log water concentration 0.88# 0.70 to 1.07
Bromodichloromethane Intercept 1.21* 0.001 to 2.41
BMI –0.01* –0.02 to –0.002
Hot water intake –0.003# –0.004 to –0.002
CYP2D6*1/*4 –0.10 –0.25 to 0.05
CYP2D6*4/*4 0.2* 0.005 to 0.40
Log air concentrationj 0.76# 0.47 to 1.06
Chloroform Intercept 1.21 0.22 to 2.20
BMI –0.01** –0.02 to –0.004
Swam –0.13* –0.24 to –0.01
Hot water intake –0.003# –0.004 to –0.002
GSTT1 null 0.13* 0.02 to 0.24
Log air concentration 0.43** 0.12 to 0.75
Log water concentration 0.45* 0.03 to 0.86
Values represent the convergence of the algorithm developed with GENMOD (SAS Institute Inc.) and are parameter esti-
mates and 95% conﬁdence intervals (CIs) of variables with p < 0.05. n = 99. 
aCalculated from height and weight data (CDC 2005). bSwam in a chlorinated pool within 48 hr of doing study
activities.cConcentration of the analyte in water (µg/L).dConcentration of analyte in air (µg/m3).eUsed sauna within 48 hr of
doing study activities. fGenotype groups: *1/*1 = wild type is the comparison group; *1/*4 and *1/*3 = heterozygous exten-
sive metabolizers (should have high ratio); *4/*4, *1/*5,*5B/*5B (also referred to as *5/*5) = genetic variants with signiﬁ-
cantly decreased metabolizing activity (should have low ratio). gParticipant used household bleach or cleaners with
bleach within 48 hr of doing study activities. hGSTT1 null, compared to GSTT1 positive. iLog [concentration of analyte in
water (µg/L)]. jLog [concentration of analyte in air (µg/m3)]. *p < 0.05. **p < 0.01. #p < 0.001.Trihalomethane exposure and enzyme polymorphisms
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